Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Elaine Kilgour, Dominic G Rothwell, Ged Brady, Caroline Dive, Elaine Kilgour, Dominic G Rothwell, Ged Brady, Caroline Dive
Abstract
Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations within an individual's tumor. Patients' responses to targeted therapies are commonly followed by treatment resistance. Here, we survey liquid biopsies as alternatives to tumor biopsies to assess predictive and therapy response biomarkers. We examine the potential of liquid biopsies to meet the challenges of minimal residual disease monitoring after curative intent treatment for earlier detection of disease recurrence. We focus on blood, the most commonly collected minimally invasive clinical sample, and on the two most widely studied assays, circulating tumor DNA and circulating tumor cells.
Keywords: circulating tumor DNA; circulating tumor cells; liquid biopsy; minimal residual disease monitoring; personalized cancer medicine; predictive biomarkers; sensitivity and specificity; targeted and immunotherapy; treatment resistance; treatment response biomarkers.
Conflict of interest statement
Declaration of Interests Research funding has been received by C.D. from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, Clearbridge Biomedics, Angle PLC, Menarini Diagnostics, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Thermo Fisher. C.D. is on the advisory board and has received consultancy fees/honoraria from AstraZeneca and Biocartis.
Copyright © 2020. Published by Elsevier Inc.
Source: PubMed